PARP1 MEDIATED PARYLATION CONTRIBUTES TO MYOGENIC PROGRESSION AND GLUCOCORTICOID TRANSCRIPTIONAL RESPONSE



Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection

The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the PS-100 coronavirus-2 (CoV-2), continues to wreak havoc globally.As novel vaccines are being discovered and developed, small molecule drugs still constitute a viable treatment option for SARS-CoV-2 infections due to their advantages such as

read more